source
- Roche to launch Phase 2 trial of petrelintide and enicepatide combination for obesityRoche announced it will begin a Phase 2 study this year testing a combination of its two obesity candidates, petrelintide and enicepatide. The company describes petrelintide as having a potentiall…
- Lilly presents safety data on obesity drug retatrutide, noting rare cardiac eventsEli Lilly reported new safety and tolerability findings for its next-generation obesity therapy retatrutide at the American Diabetes Association annual meeting. In the study, 7 of the 403 particip…